Meta Pixel

News and Announcements

Natural Health Product Manufacturer with 22,000+ Terpene Products Sold | Selling to 120+ Outlets

  • Published July 11, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Primal Organix is a natural health product manufacturer whose botanical terpene supplement drops interact with the human endocannabinoid system, enabling people to manage a range of health conditions and promote wellbeing.

Primal Organix addresses the most common chronic health conditions (e.g. mental health, respiratory, and sleep disorders) with an all-natural alternative solution to pharmaceutical drugs.

Primal Organix has generated A$792K in sales revenue having sold 22,000+ products to 120+ outlets (e.g. retail health food stores and pharmacies).

Register Interest

Investment Highlights

  • Primal Organix has generated A$792K in sales revenue and has sold 22,000+ products.

  • Product margin is more than 80% as a unit costs A$6.50 to manufacture and sells at a wholesale price of A$36.

  • Primal Organix sells to 120+ outlets (e.g. retail health food stores and pharmacies)

  • CEO Mark Garbelotto is an experienced business owner with a strong track record in sales. His first business generated millions of dollars in sales. Through his second business, the Australian Academy of Sales, he has trained over 10,000 people in increasing sales revenue.

  • Chief Science Officer Frank Giampieri has developed products to effectively manage his own disabling injury pain and has been working with doctors, specialists, and pharmacists to use his natural products to treat patients.

  • The global natural health supplements market is forecast to grow at an 8.0% CAGR to nearly A$100B by the end of 2024.

Investment Offering

Primal Organix is raising A$5M to expand its product range to include medical cannabis and nutraceutical hemp as well as to enter new global markets.

“The census shows that over eight million Australians have a long-term health condition. The WHO reports that mental health conditions are increasing worldwide, with depression and anxiety costing the global economy A$1T each year. 

People want to overcome their health challenges with a safe, non-addictive, non-pharmaceutical solution. Terpene blended health products that work in conjunction with the endocannabinoid system will be the next wave in health and medicine.”

Mark Garbelotto

CEO

Register Interest

Capital Insights
Why Are Fewer Companies Going Public?

The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.

Join over 45,000+ sophisticated investors

Join Now